Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q2 2025 Earnings Presentation
17 slides from Bioporto A/s's earnings presentation, Aug 15, 2025
Slide 1: Interim report Q2 2025 Investor Presentation
Interim report Q2 2025 Investor Presentation BioPorto A/S Hellerup, August 15, 2025 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights for the second quarter of 2025
Highlights for the second quarter of 2025 TOTAL REVENUE (Q2 2025) ✓ Strong revenue growth of 15% compared to Q2 2024 driven by NGAL sales, which increased 39% DKK 10.6 million 15% increase compared to Q2 ✓ US NGAL research use only (RUO) sales continued to increase in the second 2024 quarter of 2025
Slide 4: Status on commercial launch and adult study
Status on commercial launch and adult study
Slide 5: The ProNephro AKI (NGAL) adult study progressing as planned with submission end 2026
The ProNephro AKITM (NGAL) adult study are progressing as planned with submission end 2026 • Patient enrollment in the US clinical cut-off study for ProNephro AKI (NGAL) is progressing as planned and reaching the final phase. • The cut-off study is the first of two studies focused on defining a cut-
Slide 6: Receipt of first US order for ProNephro AKI (NGAL) marks key initial step
Receipt of first US order for ProNephro AKITM (NGAL) marks key initial step in the commercial launch • First step in the commercial launch was initiated with the first purchase order for ProNephro AKI (NGAL) for the US market on the Roche cobas® c501 analyzer • The next step involves submitting ProN
Slide 7: Financial results Q2 2025
Financial results Q2 2025
Slide 8: Solid revenue growth in Q2 2025 vs Q2 2024
Solid revenue growth in Q2 2025 vs Q2 2024 Revenue Q2 2025 vs Q2 2024, DKKm Revenue per quarter, DKKm H1 2025 vs H1 2024 Total revenue +15% US NGAL +23% 1.4m ROW NGAL +71% DKK 18.3m -2% 10.6 10.6 +39% 9.5 9.7 9.2 9.2 2.1m 8.6 8.0 7.7 7.7 7.8 7.5 6.6 Total NGAL revenue 5.4 -16% -0.5m 3.2 DKK 12.1m +5
Slide 9: Clinical study costs impacts adjusted EBITDA loss
Clinical study costs impacts adjusted EBITDA loss Adjusted EBITDA loss, DKKm • Adjusted EBITDA loss of 28.1 DKK 18.4m in Q2 2025 19.6 19.5 18.4 vs. DKK 16.2m in Q2 16.2 2024 • The increase in EBITDA loss in Q2 2025 is due to Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 clinical costs and increased headco
Slide 10: Completion of direct issuance in April 2025
Completion of direct issuance in April 2025 • On April 15, BioPorto successfully completed a direct issuance of 25,000,000 new shares at market price, providing net proceeds of 33,505,000, despite challenging financial market conditions • The raised capital is expected to fund activities through ear
Slide 11: Strategic roadmap and milestones towards 2029
Strategic roadmap and milestones towards 2029
Slide 12: Strategic milestones towards 2029
Strategic milestones towards 2029 Strategic initiatives Targets for 2025-2026 Targets for 2027-2029 • Interim data & Enrollment of the first patient in the AKI (NGAL) • NGAL Label expansion (FDA / IVDR) to Adult Study and validation study in Q3/Q4 2025 increase the serviceable market NGAL label • FD
Slide 13: Important future milestones
Important future milestones - Full execution of objectives outlined in 2024 Strategic Plan FDA clearance First patient US Interim analysis First patient US Last patient FDA submission Expected US Adult Study for ProNephro enrollment for and preliminary enrollment for US enrollment of ProNephro clear
Slide 14: Aspirations of targeting USD +100 million revenue in 2029
Aspirations of targeting USD +100 million revenue in 2029 Until 2026 • Total revenue of DKK 80-125m by expanding ProNephro AKI (NGAL) sales • Cash flow positive & EBITDA neutral by • Revenue: DKK +700m (USD +100m) end 2026 at the earliest • Increasing profitability • Cash flow positive Towards 2029
Slide 15: Financial outlook
Financial outlook
Slide 16: 2025 Financial Guidance has been narrowed
2025 Financial Guidance has been narrowed • Based on the results for the first half of 2025 and better Adjusted EBITDA loss in 2025 visibility for the remainder of Target total revenue in 2025 2025, we narrow full year guidance • Total revenue is expected to be DKK 45-50m, previously DKK 45-60m DKK
Slide 17: Q&A Contact
Q&A Contact Niels H. Nielsen, CFO – nhn@bioporto.com Hanne S. Foss, Head of Investor Relations – hsf@bioporto.com +45 4529 0000 | bioporto.com